Fragment 176-191 & CJC-1295 & Ipamorelin Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Fragment 176-191 & CJC-1295 & Ipamorelin Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Unmodified C-terminal fragment (residues 176–191) of human growth hormone studied in vitro and in animal models for lipolytic and anti-cancer drug-delivery applications.

The C-terminal hGH fragment is proposed to stimulate lipolysis in adipocytes by engaging the beta-3 adrenergic receptor (β3-AR) pathway, upregulating hormone-sensitive lipase (HSL) activity to mobilize stored triglycerides. Research in obese rodent models using the closely related AOD-9604 (Tyr-hGH 177-191) demonstrated that lipolytic effects were abolished in β3-AR knockout animals, implicating this receptor as a primary mediator; these findings are commonly extrapolated to the unmodified fragment, though direct mechanistic validation in independent studies of hGH 176-191 itself is limited. The fragment does not appear to bind the canonical growth hormone receptor and is not reported to elevate circulating IGF-1 or promote somatogenic growth in the preclinical models examined. A 2022 in vitro study (PMID 35783198) explored an unrelated application, demonstrating that hGH fragment 176-191 enhanced cytotoxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells in molecular docking and cell-viability assays, suggesting possible utility as a cancer drug-delivery component.

Molar mass

1859.1 g/mol

Short-acting synthetic GHRH(1-29) analog, chemically identical to CJC-1295 apart from lacking the C-terminal drug affinity complex (DAC) moiety, giving it a much shorter circulating exposure than the DAC form and no peer-reviewed human pharmacokinetic characterization to date.

Like CJC-1295, this analog is designed to bind GHRH receptors on pituitary somatotrophs and stimulate pulsatile growth hormone release, using the same set of proteolysis-resistant amino-acid substitutions relative to native human GHRH. Because it lacks the DAC maleimide group, it is not expected to form the covalent albumin adduct that gives the DAC form its multi-day exposure; without that depot mechanism its circulating half-life is expected to more closely resemble unmodified GHRH(1-29) analogs. A 2026 peer-reviewed narrative review (Dominikowski et al., Front Endocrinol, PMID 42395176) states directly that 'CJC-1295 without DAC' remains essentially uncharacterised in the peer-reviewed human literature: no controlled clinical studies have directly evaluated this specific compound in humans, and claims about physiologic GH pulsatility or body-composition effects are extrapolated from related unmodified GHRH(1-29) analogs (e.g., sermorelin) and non-academic sources rather than from direct evidence on this molecule.

Molar mass

3367.9 g/mol

Synthetic pentapeptide GHS-R1a agonist that triggers pulsatile GH release with high selectivity; minimal cortisol or prolactin co-elevation. Research use only.

Ipamorelin binds and activates GHS-R1a (the ghrelin receptor), a Gq/11-coupled GPCR expressed predominantly on anterior pituitary somatotrophs and hypothalamic arcuate nucleus neurons. Receptor engagement activates phospholipase C, generates inositol trisphosphate, mobilises intracellular calcium, and triggers exocytosis of stored growth hormone. Ipamorelin acts synergistically with endogenous GHRH to amplify pulsatile GH release while also partially suppressing somatostatin tone in the hypothalamus. A key pharmacological distinction from other GHRPs is its high receptor selectivity: at physiological concentrations it does not meaningfully activate adrenocortical or lactotroph pathways, so cortisol and prolactin co-elevation are minimal compared with GHRP-2 or GHRP-6.

Molar mass

711.9 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID 28400207 — COMPONENT-LEVEL (CJC-1295 class + ipamorelin), NOT blend-level. Systematic review of GH secretagogues; flags decreased insulin sensitivity and elevated blood glucose as class-level adverse signals. Does not distinguish CJC-1295 DAC vs No-DAC.
• Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. JAAOS Glob Res Rev. 2026;10(1):e25.00236. PMID 41490200 — COMPONENT-LEVEL (ipamorelin, CJC-1295, AOD-9604 individually), NOT blend-level. Narrative review; notes GH secretagogues activate the IGF-1 axis.
• Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. PMID 41476424 — COMPONENT-LEVEL, NOT blend-level: explicitly discusses the CJC-1295 + ipamorelin two-peptide combination (not the three-peptide blend, and not Fragment 176-191), and does not distinguish CJC-1295 DAC vs No-DAC. Notes findings are largely unvalidated in human trials.
• Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. PMID 41966639 — COMPONENT-LEVEL (GH secretagogues generally), NOT blend-level review of approved and unapproved peptide therapies.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Subcutaneous injection (SC) is the dominant COMMERCIAL format for this blend as sold (lyophilized 12mg vial, reconstituted for SC injection; several vendors sell a bac-water + syringe kit). No component has a formal human SC pharmacokinetic study specific to the exact form used in this blend: the only published human SC RCT among this peptide family is for CJC-1295 WITH DAC (Teichman et al. 2006) — a related but pharmacologically distinct, long-acting compound NOT used here (this blend uses CJC-1295 No-DAC / Mod GRF 1-29, which is short-acting). Ipamorelin's own published human data (Gobburu et al. 1999 PK study; the completed postoperative-ileus RCTs) used IV administration, not SC. No study has examined the three-component blend as a combined unit by any route.

No PK study of the Fragment 176-191 + CJC-1295 No-DAC + Ipamorelin blend as a unit administered SC. Component-level only: CJC-1295 No-DAC (Mod GRF 1-29, this blend's actual component) has no formally published human SC half-life — the only formal SC RCT half-life in this peptide family (5.8–8.1 days) belongs to CJC-1295 WITH DAC (Teichman et al. 2006), a related but distinct, longer-acting compound not used here. Ipamorelin and Fragment 176-191 also have no published human SC PK study.

Bioavailability: No published SC bioavailability or half-life data exist for CJC-1295 No-DAC, Ipamorelin, or Fragment 176-191 via SC injection. For context only, not applicable to this blend: CJC-1295 WITH DAC (a different, longer-acting compound) has a formally characterized SC half-life of 5.8–8.1 days via albumin binding (Teichman et al. 2006, PMID 16352683). CJC-1295 No-DAC's own human half-life is not formally established in the literature retrieved this pass — commonly repeated vendor/community claims of a '~30 minute' no-DAC half-life could not be corroborated from a primary PK source (PMID 42395176 does not report one) and are NOT asserted here; treat as short-acting only, qualitatively, fail-closed.

A vendor/commercial packaging convention (all 5 tracked vendors sell this blend as an SC-reconstituted vial), not a studied route for the specific components sold. Never conflate the DAC form's RCT-derived half-life with the No-DAC form actually in this blend.

Ipamorelin IV infusion studied in healthy male human volunteers (dose-escalation, 5 infusion rates) — a genuine component-level finding for the actual peptide in this blend. AOD9604 (fragment 177-191, closely related to but distinct from Fragment 176-191) separately studied IV in pilot human trials and in pig/rat PK studies.

Bioavailability: Ipamorelin IV: dose-proportional PK, terminal half-life ~2 h, clearance 0.078 L/h/kg, Vdss 0.22 L/kg; GH peak at 0.67 h post-infusion — this is Ipamorelin's own data. AOD9604 IV half-life in porcine models ~3 min with rapid sequential amino-terminal degradation — this is the related-analog data, not Fragment 176-191 itself.

Gobburu et al. 1999 (Pharm Res) is the primary human IV PK/PD source for ipamorelin, a real component of this blend. The AOD9604 IV data (Moré et al. 2014, JOEM) are included only as the closest studied analog of Fragment 176-191, since no direct human PK data exist for Fragment 176-191 itself. No IV data exist for either CJC-1295 form.

AOD9604 (the closest analog of Fragment 176-191) studied orally in six human clinical trials including two oral Phase IIb studies (300 and 500 obese adults). No oral human data exist for Fragment 176-191 itself, CJC-1295 (either form), or ipamorelin.

Bioavailability: AOD9604 was orally active in human trials (capsules/tablets, 0.25–54 mg doses) via a proprietary delivery system; direct oral bioavailability data for Fragment 176-191 itself are not available. Oral peptide bioavailability is profoundly affected by gastrointestinal proteases.

Oral stability ≠ oral absorption. AOD9604's oral activity is attributed to N-terminal tyrosine stabilization not present in Fragment 176-191, so this data cannot be directly extrapolated to the actual blend component. Development of AOD9604 was halted in 2007 after insufficient lipolytic efficacy in a 24-week trial. No oral data exist for either CJC-1295 form or ipamorelin.

Ipamorelin intranasal absorption evaluated in an animal PK study (comparative study with other GHRPs). No intranasal data exist for either CJC-1295 form or Fragment 176-191.

Bioavailability: After intranasal application, ipamorelin bioavailability was estimated at approximately 20%. Comparative GHRPs (NNC 26-0235, NNC 26-0194, GHRP-2) showed ~50% nasal bioavailability in the same study.

Johansen et al. 1998 (Xenobiotica) is the primary source; an animal-model comparative PK study, not a human finding. No human intranasal data for ipamorelin were identified.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $6.67 · median $7.33 · p75 $8.00 · 5 researched vendors

Legit, COA-backed band: $6.00–$8.50/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$61

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Vendor-claimed purity for the blend ranges from ≥98% to >99% (Core Peptides and Biotech Peptides claim >99%; USA Peptide Science claims ≥98%). No independent-lab aggregate purity report specific to the combined THREE-component blend was found. Component-level, not blend-level: Janoshik-verified single-batch testing (Chameleon Peptides) reports CJC-1295 No-DAC (the form actually in this blend) at 99.624% purity, versus CJC-1295 WITH DAC (a different compound, not in this blend) at 98.178%; a historical ipamorelin batch tested at 99.543% purity.

Independent labs cited for this compound

No FDA recall or market withdrawal was found specifically targeting a 'Fragment 176-191 & CJC-1295 & Ipamorelin Blend' product (or any component individually). As unapproved/RUO-labeled research chemicals sold outside the regulated supply chain, FDA action takes the form of Category-2 bulk-substance restrictions, import detention, and enforcement letters rather than Class I/II/III recalls (see events). Reported honestly as an empty recall result — none found — not invented.

Buyer red-flag checklist

• No FDA-approved drug application exists for HGH Fragment 176-191, CJC-1295 (either form), ipamorelin, or any product marketed as this three-peptide blend.
• All three components were placed in interim 503A Category 2 in Sept 2023; nominations were later withdrawn and referred to PCAC for review (exact withdrawal date unconfirmed) — none of this is FDA approval or authorization to compound.
• Vendor marketing for CJC-1295-containing products (e.g. product-page copy citing large GH/IGF-1 fold-increase figures) sometimes traces to the DAC-conjugated variant's published pharmacology (Teichman et al. 2006) while marketing this blend's No-DAC (Mod GRF 1-29) component — the two forms have materially different pharmacokinetics; such figures should not be read as describing the specific peptide actually sold here.
• No independent lab test was found for the exact three-component blend; purity/amount data exist only for a two-component CJC-1295-No-DAC + ipamorelin sub-blend and for individual components.
• Vendor purity claims (>99%) are self-reported; only 2 of the 5 tracked vendors advertise any COA or third-party test for this specific product.
• FDA Import Alert 66-71 targets unapproved HGH products at US ports; its applicability to the CJC-1295/ipamorelin GH-secretagogue components (not HGH itself) is ambiguous, and it does not name this blend.
• Gray-market 'research grade' peptide vendors sell this blend labeled 'not for human use' while marketing implies human therapeutic benefits — a regulatory mismatch flagged by FDA and ProPublica reporting.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent-lab aggregate quantifying underdosing/mislabeling prevalence for the combined three-component blend was found. Component-level, not blend-level: Janoshik testing of a Chameleon Peptides CJC-1295 No-DAC + Ipamorelin two-component blend (Batch 002 — the No-DAC form actually used in this blend) measured close to label (Ipamorelin 5.61/4.86 mg and CJC-1295 No-DAC 5.12/5.07 mg vs 5 mg label claims each). A separate single-component CJC-1295 No-DAC 5 mg vial tested at 4.57 mg (91.4% of label). No independent test was found for the exact three-component blend (Fragment 176-191 included), so a prevalence figure cannot be calculated for it.

• FDA Import Alert 66-71 ('Detention Without Physical Examination of Unapproved Human Growth Hormone', rev. 04/07/2026) authorizes DWPE of unapproved HGH products, including lyophilized powders offered as APIs for compounding/reconstitution. It most directly targets the Fragment 176-191 / AOD-9604 component (an HGH-derived fragment); its applicability to CJC-1295 (either form) and ipamorelin — GH secretagogues/GHRH analogues, not HGH itself — is less clear and not established by the alert naming them specifically. Distributing HGH for unapproved uses violates 21 U.S.C. §333(e)(1) (FD&C Act §303(e)(1)), carrying up to 5 years imprisonment (10 years if involving a minor).FDA Import Alert 66-71
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

The three-peptide blend itself is not named on the WADA Prohibited List (no product-level schedule exists for a named blend). Per component: Fragment 176-191/AOD-9604 is explicitly named as a 'growth hormone fragment' under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) in WADA's dated 2019 and 2023 Prohibited Lists — a confirmed, primary-sourced fact. CJC-1295 (a GHRH analogue) and ipamorelin (a growth hormone secretagogue) fall under the same S2 category by class, but this pass could not confirm their specific by-name enumeration in the current list against a primary dated WADA document (the general prohibited-list page was checked; a dated PDF naming them specifically was not retrieved) — treat their S2 status as class-level inference pending a stronger citation, not a confirmed named listing.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-experimentation community with no controlled trials of the blend.
• Vendor-affiliated or promotional posts present in forums/blogs.
• Anecdotal self-report only; no biomarker verification.
• Survivorship bias toward users who perceived effects.
• Blend-ratio confusion introduces dosing-report noise.
• A single dramatically-titled Reddit thread ('CJC-1295/Ipamorelin almost killed me last night') could not be independently corroborated this pass and is treated as illustrative of the adverse-reaction-episode theme, not a confirmed severe-event rate.
• Secondary vendor-blog/aggregator sources discussing 'CJC-1295' pharmacology rarely distinguish the DAC vs No-DAC form; community discourse referencing GH/IGF-1 fold-increase figures likely inherits that same conflation (see the CJC identity note above and quality.redFlags).

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

A research-use-only three-peptide blend of the HGH fragment 176-191, the GHRH analog CJC-1295, and the growth hormone secretagogue Ipamorelin. US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet